Tweet

@HFA_President

@ESC_Journals

@HFA_President

More from @HanCardiomd

Henry Han , MBBS, MD

@HanCardiomd

May 21

@escardio

#HFA_ESC @escardio scientific updates

Patient profiling in HFpEF

What are therapeutic options for #HFpEF in 2023 ?

#HeartFailure2023 @NicolasGirerd @DrMarthaGulati @Marta33717088 @LauraMeems @CharlesFauvel @Giccardio_fr @HFA_President @WilfriedMullens @escardio

@markcpetrie20

Numbers of emerging treatments are under investigation for HFpEF

#HeartFailure2023 @markcpetrie20 @DrMarthaGulati @Marta33717088 @LauraMeems @CharlesFauvel @Giccardio_fr @HFA_President @WilfriedMullens

@MarcoMetra

📍#SGLT2i should be initiated in all HFpEF patients without contraindications, ideally once stable during hospitalization for index event.

#HeartFailure2023 @MarcoMetra @HFA_President @WilfriedMullens

Read 4 tweets

Henry Han , MBBS, MD

@HanCardiomd

May 20

@lamcardio

State of the art: Are #HFpEF phenotypes, a needed classification?

#Hypertension phenotype by Dr. Michele Senni

#HeartFailure2023 @lamcardio @JavedButler1 @JamalRanaMD @AHajduczok @WilfriedMullens @FH_Verbrugge @ShelleyZieroth

Has #hypertension a greater prognostic impact in HFpEF than #HFrEF?

Should we treat HTN differently in
#HFpEF patients compared to patients without HF?

What are the current evidences ?

#HeartFailure2023

@escardio

#Spironolactone Use and Improved
Outcomes in Patients With #HFpEF With Resistant #Hypertension

#HeartFailure2023 @escardio

Read 4 tweets

Henry Han , MBBS, MD

@HanCardiomd

Oct 19, 2022

@GeraldMaurer

The natural history of SMR and its longitudinal progression until the onset of severe #MR

There are two distinct patterns of progression of SMR patients with various implications

academic.oup.com/ehjcimaging/ad… #EHJCVI @GeraldMaurer @denisamuraru @alessia_gimelli @JGrapsa @iamritu

Cluster 1 had higher LAV, LVEDV, and #LVESV, along with lower EF and less septal thickness, but slower EF and LVESV progression compared with Cluster 2.

Moderate SMR was more frequent in Cluster 1, whereas Cluster 2 had more non/trivial and mild #SMR

#EchoFirst #EHJCVI

On time-to-event analysis, there were no differences in terms of mortality and occurrence of MV interventions, #LVAD , and HTx

A higher likelihood of MV interventions (including Sx and #TEER) was observed in Cluster 2 type with fewer LVAD procedures

#EchoFirst #EHJCVI

Read 6 tweets

Henry Han , MBBS, MD

@HanCardiomd

Oct 19, 2022

@ESC_Journals

This study shows that more than 1/3 of patients with new-onset #HeartFailure have #RVD

📌During up-titration of #GDMT, 49% show normalization of RV function

📌The improvement is associated with better outcomes, independent of LV function

onlinelibrary.wiley.com/doi/abs/10.100… @ESC_Journals

RV dysfunction as a predictor of clinical outcome in newly-Dx #HeartFailure

This analysis demonstrates #RVD at baseline and follow-up was associated with a higher risk of all-cause ☠️ [ HR- 1.66 (1.27-2.16) ] and HF 🏥 [ HR -2.20 (1.51-3.21) ]

onlinelibrary.wiley.com/doi/abs/10.100… #EJHF

Recovery of RV function is associated with better outcomes

This study also stated that improvement of TAPSE to ≥ 17mm during follow-up was associated with a reduction in all-cause ☠️ and #HeartFailure 🏥 (HR- 0.56[0.31-0.99] ), independent of
baseline TAPSE, age, sex, and LVEF

Read 4 tweets

Henry Han , MBBS, MD

@HanCardiomd

Oct 3, 2022

@JACCJournals

#COAPT Risk Score for Death or #HeartFailure 🏥

📍Simple risk score using 4 clinical (COPD, #NYHA class, Afib/Aflut, and #CKD)

📍4 #EchoFirst (#LVEF, LVESD, RVSP, and #TR) variables + 1 treatment-related variable (#TEER)

jacc.org/doi/10.1016/j.… @JACCJournals @GreggWStone

@JACCJournals

Using data from the #COAPT trial, a simple risk score using 4 clinical and 4 Echo parameters + 1 treatment-related variable (#TEER), which provides prognostic insight into the 2-year rates of ☠️ or #HeartFailure 🏥 in patients with symptomatic #HF and severe #FMR

@JACCJournals

There was consistent benefit from TEER with MitraClip across all risk strata

FMR and HF pts are at ⬆️ risk for ☠️ and recurrent HFH, despite best Med Rx & invasive Tx including MV TEER

👉🏻Future studies are needed to externally validate the COAPT risk score in pts with HF & FMR

Read 6 tweets

Henry Han , MBBS, MD

@HanCardiomd

Jul 15, 2022

#Immunosuppressive therapy in virus-negative inflammatory CMP : 20-year follow-up of the #TIMIC trial

Immunosuppressive Tx of virus-negative inflammatory #CMP is associated to a persistent improvement of LV
function and better outcomes during long-term follow-up

#HeartFailure

#Immunosuppressive Tx promoted an improvement in cardiac function in 88% of the cases compared the placebo group

A persistent ⤴️ in the #LVEF is seen in long -term (up to 20 years) clinical outcomes of the whole cohort of 85 patients originally enrolled in the #TIMIC trial

@ESC_Journals

Recurring virus-negative myocarditis responding to #immunosuppressive therapy

EKG showing LBBB (A) resolving after therapy (B)

(C and D) Echo apical view showing recovery of LV dysfunction from EF -28% ➡️ up to 51%

#HeartFailure #EchoFirst @ESC_Journals academic.oup.com/eurheartj/adva…

Read 6 tweets

Share this page!

Enter Twitter Thread URL to Unroll

Henry Han , MBBS, MD

People who liked this thread also liked...

Try unrolling a thread yourself!

More from @HanCardiomd

Henry Han , MBBS, MD

Henry Han , MBBS, MD

Henry Han , MBBS, MD

Henry Han , MBBS, MD

Henry Han , MBBS, MD

Henry Han , MBBS, MD

Did Thread Reader help you today?

Don't want to be a Premium member but still want to support us?

Send Email!